194 results about "Acepyrylene" patented technology

The invention discloses a supported ruthenium complex catalyst. The supported ruthenium complex catalyst comprises a porous solid carrier, and a ruthenium complex, a metal assistant and a nonmetal assistant which are supported on the surface of the carrier, and the ruthenium complex is one or more of a polypyridine ruthenium complex, a ruthenium porphyrin ruthenium complex, an aromatic hydrocarbonruthenium complex, a cyclic metal ruthenium complex, a DMSO ruthenium complex, an amine ruthenium complex and an imine ruthenium complex; the metal assistant is salt of one or more of In, Bi, Ba, Sr,Fe, Mn, Zn, Cs, Ca and Sn; the nonmetal assistant is an ionic liquid; and a ratio of the mass of the porous solid carrier to the theoretic mass of ruthenium in the ruthenium complex to the mass of the metal in the metal assistant to the mass of the nonmetal assistant is 100:(0.01-2):(0.01-3):(1-30). The catalyst has a very high stability in an acetylene hydrochlorination reaction, no obvious lossof the ruthenium is detected after the catalyst runs for 8000 h, the highest acetylene conversion rate reaches 99.95% or more, and the highest vinyl chloride selectivity reaches 99.95% or more.

Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D3, 2-methylene-1α,25-dihydroxy-(17E)-17(20)-dehydro-19-nor-vitamin D3, 2-methylene-19-nor-(24R)-1α,25-dihydroxyvitamin D2, 2-methylene-(20R,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20R)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20S)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol, (2-(3′hydroxypropyl-1′,2′-idene)-19,23,24-trinor-(20S)-1α-hydroxyvitamin D3, 2-methylene-18,19-dinor-(20S)-1α,25-dihydroxyvitamin D3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and / or a solute thereof. Compounds that activate retinoic acid receptors, such as retinoyls and retinoyl esters, include 13-cis-retinoic acid, all-trans-retinoic acid, (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexeneyl)nona-2,4,6,8-tetraenoic acid, 9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-napthoic acid, 4-[1-(3,5,5,8,8-pentamethyl-tetralin-2-yl)ethenyl]benzoic acid, retinobenzoic acid, ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate, retinoyl t-butyrate, retinoyl pinacol, retinoyl cholesterol, an isomer thereof, a prodrug thereof for oral compositions, an ester thereof, a salt thereof, and / or, a solute thereof. Combinations of such active ingredients demonstrate synergistic efficacy.

The present invention discloses an improved and novel process for the preparation of erlotinib (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine) of formula (1), which comprises: (i) demethylation of commercially available 6,7-dimethoxy-4(3H)-quinazolinone of formula (8); acetylation using acetic anhydride; (iii) introduction of a leaving group at C-4 position in quinazolinone; (iv) condensation with 3-ethynylaniline to get novel compound of formula (12); (v) deacetylation to get novel dihydroxy compound of formula (13); and (vi) O-alkylation with 2-iodoethylmethyl ether to get the erlotinib base of formula (1). Erlotinib base is purified by recrystallization from ethyl acetate to get a HPLC purity of >99.5%. Salt formation of this base with hydrogen chloride gave pharmaceutically acceptable erlotinib hydrochloride of formula (1a) with a HPLC purity of >99.8%. Erlotinib hydrochloride is useful for the treatment of proliferative disorders, such as cancers, in humans.

The present invention relates to one kind of polyfluoro substituted diphenyl acetylene derivative and its composition, preparation process and use as the liquid crystal material for display. The polyfluoro substituted diphenyl acetylene derivative has the general expression as shown, great optical anisotropy, relatively low viscosity, relatively wide nematic phase temperature range, excellent low temperature compatibility, facile material, and simple and feasible synthetic path, and is suitable for use as displaying liquid crystal material with improved response speed and driving voltage. The liquid crystal composition has excellent performance, including greatly improved response speed and low temperature compatibility, and may be used in liquid crystal display of TN mode, STN mode, TFT mode, etc.

The invention relates to a method for preparing a super capacitor on the basis of a three-dimensional porous graphene composite material. The method comprises the following steps of grinding and mixing the three-dimensional porous graphene composite material, acetylene black and a polytetrafluoroethylene emulsion with the mass fraction of 15 percent in the weight part ratio of (76-84):(12-18): (5-8) into electrode slurry, and uniformly dispersing the electrode slurry into a small amount of anhydrous alcohol to form paste liquid, and coating the paste liquid onto the surface of foam nickel to form a thin sheet to obtain an electrode plate; taking a polypropylene porous film as a septum, soaking the septum in electrolyte aqueous solution, placing the soaked septum between two electrode plates, and packaging to prepare the super capacitor of the two electrode plates. The method is based on the three-dimensional porous graphene composite material; when the packaging current density is 0.1 A / g, the specific capacity can be between 236 and 160f / g.

The invention discloses a method for continuously preparing a 2-aryl-benzothiophene / furan compound by utilizing an electrochemical micro-channel reaction device. The preparation method comprises the following steps: dissolving ethynyl thioanisole / phenylethynyl anisole and an iodine-containing electrolyte in water and acetonitrile to prepare a homogeneous solution, then introducing the prepared homogeneous solution into a feeding hole of an electrochemical micro-channel reaction device by utilizing an injection pump in single-strand sample introduction, and reacting under the action of a direct-current power supply to obtain the product 2-aryl-benzothiophene / furan compound; wherein the electrochemical micro-channel reaction device comprises an anode electrode, a cathode electrode, an electrolytic tank bracket, a reaction tank, the direct-current power supply and a temperature control module; wherein the reaction tank is positioned between the anode electrode and the cathode electrode, and a closed serpentine flow path is formed between the anode electrode and the cathode electrode; the anode electrode and the cathode electrode are arranged on the electrolytic tank bracket; one endsof the anode electrode and the cathode electrode are connected with each other and are connected with the direct-current power supply; and the temperature control module is embedded in the electrolytic tank bracket and is used for controlling the temperature of liquid in the reaction tank.

Cell binding agent-drug conjugates comprising bridge linkers, and methods of using such linkers and conjugates are provided.